ScienceTherapeutic Focus Areas

Lung Transplantation

Advancing a novel clinical program to prevent lung rejection

A lung transplant is a surgical procedure to replace a diseased or failing one or both lungs with a healthy lung, usually from a deceased donor. A lung transplant is reserved for people who have tried other medications or treatments, but their conditions haven’t sufficiently improved. The donor lungs must be disease-free and matched as closely as possible to the recipient tissue type. This reduces the chance that the body will reject the transplant.

A variety of diseases and conditions can damage the lungs and limit their ability to function effectively, including:

  • Chronic obstructive pulmonary disease (COPD), including emphysema
  • Scarring of the lungs (pulmonary fibrosis)
  • Cystic fibrosis
  • Alpha-1 antitrypsin deficiency
  • Sarcoidosis
  • Pulmonary hypertension
  • Lymphangioleiomyomatosis
  • Severe bronchiectasis

Lungs have the highest rate of rejection among transplanted solid organs. About a third of lung transplant recipients will experience acute rejection within the first year and the majority will develop some form of chronic rejection over the 5 years after transplant. This is a serious problem and may lead to progressive damage and loss of function in the transplanted lung.

Kamada initiated the first clinical trial designed specifically to prevent lung transplant rejection, to assess the safety of AAT IV and the effect on rate and severity of acute and chronic lung rejection as well as pulmonary infections, in subjects undergoing first lung transplantation.